双联抗血小板治疗急性冠脉综合征临床疗效观察

目的：探讨双联抗血小板治疗急性冠脉综合征（ACS）的临床疗效和安全性。方法：60例ACS患者随机分为治疗组和对照组。对照组给予阿司匹林单抗血小板治疗,治疗组采用阿司匹林＋氯吡格雷双联抗血小板治疗,治疗3个月后评价临床疗效。结果：治疗组临床疗效总有效率为93.3%,显著高于对照组（76.7%）,相比较有显著性差异（P〈0.05）;治疗后,两组LVEF、CO、E/A显著上升,与治疗前比较均有显著性差异（P〈0.05）;且治疗组与对照组比较有显著性差异（P〈0.05）。结论：阿司匹林和氯吡格雷双联抗血小板药物治疗ACS,可以强化对血小板聚集的抑制,并增强抗栓效果,值得临床应用。

Clinical study of dual anti-platelet for patients with acute coronary syndrome

Objective：To investigate the clinical efficacy and safety of dual anti-platelet for treating the patients with acute coronary syndrome（ACS）.Methods：A total of 60 patients with ACS were randomly divided into the treatment group and control group.The control group＇s patients were given the mono anti-platelet therapy of aspirin,and the treatment group＇s patients were given the dual anti-platelet treatment of aspirin combined with clopidogrel.The clinical efficacy was observed after treatment for 3 months.Results：The total effec-tive rate of treatment group was 93.3%,the control group was 76.7%,compared the difference was significant（P 0.05）;After therapy the LVEF,CO and E / A of the two groups increased significantly,compared with the prior-treatment the difference was significant（P 0.05）,and the difference was significant between the treatment group and control group（P 0.05）.Conclusion：The dual anti-platelet of aspirin combined with clopidogrel for treating the patients with ACS can enhance the inhibition of platelet aggregation and enhance the antithrombotic effect.It is worthy of clinical application.